Early myoclonic encephalopathy caused by a disruption of the neuregulin-1 receptor ErbB4

Article metrics

Abstract

The tyrosine kinase receptor ErbB4 (erythroblastic leukemia viral oncogene homolog 4) plays a crucial role in numerous neurobiological processes in the developing and adult brain. Moreover, recent molecular genetics studies implicate ErbB4 in the pathophysiology of schizophrenia. However, the phenotypic consequences of haploinsufficiency of ErbB4 are not known, as no coding mutations have been identified until now. Here, we present a patient with early myoclonic encephalopathy and profound psychomotor delay with a de novo reciprocal translocation t(2;6)(q34;p25.3), disrupting the ErbB4 gene. This patient represents the first case of haploinsufficiency for one of the ErbB family members of tyrosine kinase receptors.

Introduction

‘Early myoclonic encephalopathy’ (ILAE; OMIM 609304) is one of the catastrophic epilepsies starting in the neonatal period. Prognosis is generally poor with early death in half of the patients. The other half usually develops a therapy-resistant epilepsy with numerous mainly myoclonic seizures and developmental arrest.1 In most cases, the etiology is unknown and rare familial cases have been described.2

ErbB4 is a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinase receptors that regulate cell growth, proliferation and differentiation. This family comprises four members that share structural and functional similarities (EGFR, ErbB2-4), and interact with a variety of ligands and with each other.3 ErbB4 spans 1.15 Mb on chromosome 2q34 and has four different isoforms because of alternative splicing.4 ErbB4 is widely expressed in many adult and fetal tissues, with high expression in developing brain and heart.5 Targeted inactivation of ErbB4 in a mouse results in midembryonic lethality because of failed myocardium development.6 Rescued ErbB4 mutant mice reach adulthood but display mammary gland defects, aberrant cranial nerve connections and increased cerebellar interneurons.7 One of the most important and well-studied ligands of ErbB4 is neuregulin-1 (NRG1), and it was shown that NRG1–ErbB4 signaling is essential for neurobiological processes, such as neurogenesis, migration, synaptic plasticity and differentiation of neurons and glia.8 After the identification of NRG1 as a candidate for schizophrenia, different schizophrenia-associated SNPs in ErbB4 were also identified.9 However, in humans, the phenotypic consequences of haploinsufficiency of ErbB4 are not known, as no coding mutations or deletions have been identified until now.

Here, we present a patient with epileptic encephalopathy and profound psychomotor delay with a de novo translocation t(2;6)(q34;p25.3), disrupting the ErbB4 gene. This patient represents the first case of haploinsufficiency for one of the ErbB family members of tyrosine kinase receptors.

Patient report

The girl is the second child of normal parents, born at term with normal birth parameters after normal pregnancy. Family history is negative. Because of poor sucking, she was hospitalized at day 11, when a unilateral multicystic kidney and tubular acidosis type 4 were diagnosed.

During hospitalization, seizures were noted for the first time and initially fenobarbital was administrated. These seizures were reported as typical ‘erratic myoclonic seizures’. In addition, she had two generalized tonic–clonic convulsions during fever. The first EEG performed at day 15 was reported normal. However, in the following days and weeks, the EEG's changed, showing a pattern of suppression bursts initially more accentuating during sleep, but later also during wakefulness. Despite treatment, the frequency of seizures increased dramatically during the following months, necessitating frequent hospitalizations and additive therapy consisting of valproic acid and topiramate. Her development was severely delayed with pronounced hypotonia, absent eye contact, limited spontaneous movements, no speech development and progressive microcephaly. The therapy-resistant seizures led to her being admitted, at the age of 18 months, to an epilepsy center for children. On the basis of the patient's history, clinical observation and EEG registration, she was diagnosed with symptomatic early myoclonic encephalopathy. EEG at that time revealed a hypsarrhythmic pattern during wakefulness with periods of suppression-burst pattern during sleep (Figure 1). As expected with this diagnosis, there was almost no progress in psychomotor development and she persisted in having multiple erratic myoclonic seizures. Tonic seizures were not seen, and generalized myoclonic seizures were rare. Additional investigations, including a metabolic work-up and skin biopsy, were normal. MRI of the brain showed moderate cortical and subcortical atrophy. Chromosome analysis revealed a de novo reciprocal translocation involving chromosomes 2q and 6p, t(2;6)(q33.1;p23).

Figure 1
figure1

EEG taken during sleep at the age of 18 months showing hypsarrhythmia with periods of suppression-burst pattern. Longitudinal montage calibration 70 μV, 1 sec between lines.

Re-evaluation at the age of 4 years and 10 months shows a profoundly retarded girl showing no contact with her environment and acting at a developmental level of 4 months (Figure 2). She is microcephalic, unable to sit, with pronounced axial hypotonia and peripheral hypertonia with brisk tendon reflexes. She still has frequent daily fits of the myoclonic type, therapy resistant, compatible with early myoclonic encephalopathy.

Figure 2
figure2

Clinical pictures of the patient at age 18 months (left), and 4 years and 10 months (right).

Materials and methods

The protocol was approved by the appropriate Institutional Review Board of the University Hospital of Leuven, Belgium, and informed consent was obtained from the parents of the affected patient.

Chromosome and array comparative genome hybridization (CGH) analysis

Karyotyping was performed according to routine protocol. Arrays used in this study were constructed for total genome coverage using a 1 Mb clone set. Clone preparation, hybridization and data analysis were performed as described previously.10

Fluorescence in situ hybridization (FISH) was used to confirm results of array CGH as well as for mapping the breakpoints.

Mutation analysis of the ErbB4 and GDP-mannose 4,6-dehydratase (GMDS) genes

Primers were designed to amplify all coding exons and intron–exon boundaries of the ErbB4 and GMDS genes. Sequences are available on request. Amplification, sequencing and analyses were performed according to routine protocol.

Results

Routine karyotyping revealed a t(2;6)(q33.1;p23) in the patient (Figure 3). Karyotypes of both parents were normal. Because apparently balanced translocations can be more complex, genomic DNA of the patient was analyzed on 1 Mb array. Besides a known copy number variation, no other imbalances were detected. Subsequent FISH analysis demonstrated that the breakpoint on chromosome 2 is located in clone RP11-694B12 that shows a split signal in 2q34 and maps within the first intron of ErbB4. Therefore, the breakpoint is located between coding exons 1 and 2, disrupting the ErbB4 gene (Figure 3). Gene expression analysis was not performed because ErbB4 is not sufficiently expressed in Epstein–Barr transformed lymphoblastic cell lines (EBV-LCL). The breakpoint on chromosome 6p25.3 is located in the overlapping ends of clones RP11-323F15 and RP11-707D01, disrupting the GMDS gene (Figure 3). Quantitative RT-PCR of GMDS mRNA levels in EBV-LCL of the patient showed 50% reduction in comparison with normal controls (data not shown). The corrected karyotype based on these data is t(2;6)(q34;p25.3). The disrupted genes are orientated in opposite directions, making it unlikely that a fusion transcript is generated. Subsequent mutation analysis showed no mutations in the normal ErbB4 and GMDS alleles.

Figure 3
figure3

Schematic representation of the translocation and the two breakpoints on 2q34 and 6p25.3: (a) Partial karyotype of the patient showing the reciprocal translocation between chromosomes 2q and 6p. (b) FISH analysis on metaphase spreads of the patient with BAC clone RP11-694B12 spanning the 2q34 breakpoint showing signals on chromosome 2, and derivatives 2 and 6. (c) Schematic representation of the 2q34 breakpoint. The breakpoint-spanning clone, RP11-694B12, maps within the first intron of the ErbB4 gene, and therefore disrupts the ErbB4 gene (forward slash). The orientation of ErbB4 is indicated by the black arrow. The exons are indicated as black boxes. (d) Schematic representation of the 6p25.3 breakpoint. The breakpoint resides in the region covered by the BAC clones RP11-323F15 (signal on the derivative chromosome 2) and RP11-707D01 (signal on the derivative chromosome 6), and interrupts the GMDS gene between exons 4 and 8 (brackets). The orientation of GMDS is indicated by the arrow. The exons are indicated as black boxes. Positions of the genes and BAC clones are indicated in Mb and are based on the Ensembl view release 43, Feb 2007 (http://www.ensembl.org/Homo_sapiens/). EX exon.

Discussion

We present a patient with severe epileptic encephalopathy, diagnosed as early myoclonic encephalopathy, carrying a de novo reciprocal translocation disrupting the GMDS and ErbB4 genes.

The GMDS gene plays a role in the conversion of GDP-mannose to GDP-fucose. Deficiencies in the biosynthesis of GDP-fucose lead to leukocyte adhesion deficiency type II (LADII), which is a rare autosomal recessive disorder characterized by recurrent infections, persistent leukocytosis and severe mental and growth retardation (MIM 266265). Although it was first assumed that deficient GDP-fucose biosynthesis would cause LADII, Luhn et al11 showed that LADII is caused by a defect in a specific transporter of GDP-fucose into the Golgi. Thus far, the GMDS gene has not been associated to a specific disease, although one can assume that this disease would resemble LADII and be recessive in inheritance. Hence, we sequenced the other GMDS allele, but did not detect a mutation. Moreover, recurrent infections, immune deficiency, growth retardation and persistent leukocytosis are absent in our patient. Disruption of GMDS, therefore, most likely has no phenotypic effect, and the phenotype in the patient can be attributed to the disruption of ErbB4. Given the absence of mutation on the second ErbB4 allele, haploinsufficiency is the proposed pathogenic mechanism. The position of the breakpoint within the gene, as well as the absence of alternative splice forms starting downstream from the breakpoint, predicts a loss of function.

HER4/ErbB4 is a member of the type I receptor tyrosine kinase subfamily and serves as a receptor for the NRG family of growth factors. At the cellular level, ErbB4 is expressed by somatodendrites in cerebral cortex and hippocampus from birth to adulthood.12 The importance of this receptor during development is further demonstrated by the generation of knockout mice. These mice die during midembryogenesis because of failed development of the myocardium.6 Mice heterozygous for the inactivated ErbB4 allele displayed no obvious defects in contrast to our finding in the patient.6, 13 However, in a more recent study, Golub et al14 found that heterozygous nulls do display subtle neurological defects, such as delayed motor development and altered cue use in a Morris maze learning and memory task. Interestingly, high ErbB4 expression was shown in precursors of interneurons migrating from the medial ganglionic eminence to the developing cortex.15 A crucial role in interneuron migration and differentiation is further corroborated by an elegant study done by Flames et al.16 They showed that NRG-1/ErbB4 interaction is necessary for short/long range attraction of tangentially migrating interneurons at different stages of their journey. ErbB4-expressing interneurons migrate to the cortex through a corridor where there is expression of NRG-1, which constitutes the attractant for the migration. Loss of ErbB4 and/or NRG-1 function perturbs interneuron migration and alters the number of GABA-ergic interneurons in postnatal cortex.16 These findings might explain the occurrence of severe epileptic encephalopathy in our patient beacuse of a reduced number or function of cortical GABA-ergic interneurons. Defects in interneuron migration and function have already been associated with epilepsy in humans, as is the case for ARX.17, 18 Mutations in ARX are responsible for X-linked infantile spasms (ISSXs) and more recently for early infantile epileptic encephalopathy (EIEE) or Ohtahara syndrome.19 Another monogenic cause of early epileptic encephalopathy, almost exclusively restricted to female patients, are mutations in the X-linked CDKL5 gene20, 21, 22 This gene was initially identified in female patients with the early seizure variant of Rett syndrome.23, 24 In this respect, it is interesting to mention that Pescucci et al25 reported a girl, who was presented with severe epilepsy and Rett-like features carrying a deletion in 2q34 encompassing the ErbB4 gene.

Although the ARX and CDKL5-associated epilepsy phenotypes can be clearly differentiated from the present case, it would be interesting to analyze ErbB4 in a larger cohort of patients presenting with unexplained early epileptic encephalopathy.

In contrast to the central nervous system defects, our patient does not have a cardiac defect or signs of cardiomyopathy, suggesting that the amount of residual ErbB4 protein during fetal heart development and postnatal heart function is sufficient. Alternatively, we cannot exclude an important or redundant role for other ErbB family members, especially ErbB2, during heart development in humans in contrast to mice. In addition, our patient has a unilateral multicystic kidney. Although two of the four known ErbB4 isoforms, JM-a and CYT-2, are specifically expressed in the kidney, renal anomalies were not reported in the ErbB4 −/− mice, neither in the surviving rescued mice.6, 7 Again, interspecies differences might account for this discrepancy, but we can not exclude other genetic or environmental factors.

References

  1. 1

    Panayiotopoulos CP : A Clinical guide to Epileptic Syndromes and their Treatment. Oxford: Bladon Medical Publishing, 2002.

  2. 2

    Bruel H, Boulloche J, Chabrolle JP, Layet V, Poinsot J : Early myoclonic epileptic encephalopathy and non-ketotic hyperglycemia in the same family. Arch Pediatr 1998; 5: 397–399.

  3. 3

    Britsch S : The neuregulin-I/ErbB signaling system in development and disease. Adv Anat Embryol Cell Biol 2007; 190: 1–65.

  4. 4

    Junttila TT, Sundvall M, Maatta JA, Elenius K : Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc Med 2000; 10: 304–310.

  5. 5

    Srinivasan R, Poulsom R, Hurst HC, Gullick WJ : Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol 1998; 185: 236–245.

  6. 6

    Gassmann M, Casagranda F, Orioli D et al: Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 1995; 378: 390–394.

  7. 7

    Tidcombe H, Jackson-Fisher A, Mathers K, Stern DF, Gassmann M, Golding JP : Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality. Proc Natl Acad Sci USA 2003; 100: 8281–8286.

  8. 8

    Anton ES, Ghashghaei HT, Weber JL et al: Receptor tyrosine kinase ErbB4 modulates neuroblast migration and placement in the adult forebrain. Nat Neurosci 2004; 7: 1319–1328.

  9. 9

    Law AJ, Kleinman JE, Weinberger DR, Weickert CS : Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum Mol Genet 2007; 16: 129–141.

  10. 10

    Vermeesch JR, Melotte C, Froyen G et al: Molecular karyotyping: array CGH quality criteria for constitutional genetic diagnosis. J Histochem Cytochem 2005; 53: 413–422.

  11. 11

    Luhn K, Wild MK, Eckhardt M, Gerardy-Schahn R, Vestweber D : The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. Nat Genet 2001; 28: 69–72.

  12. 12

    Mechawar N, Lacoste B, Yu WF, Srivastava LK, Quirion R : Developmental profile of neuregulin receptor ErbB4 in postnatal rat cerebral cortex and hippocampus. Neuroscience 2007; 148: 126–139.

  13. 13

    Golding JP, Trainor P, Krumlauf R, Gassmann M : Defects in pathfinding by cranial neural crest cells in mice lacking the neuregulin receptor ErbB4. Nat Cell Biol 2000; 2: 103–109.

  14. 14

    Golub MS, Germann SL, Lloyd KC : Behavioral characteristics of a nervous system-specific erbB4 knock-out mouse. Behav Brain Res 2004; 153: 159–170.

  15. 15

    Yau HJ, Wang HF, Lai C, Liu FC : Neural development of the neuregulin receptor ErbB4 in the cerebral cortex and the hippocampus: preferential expression by interneurons tangentially migrating from the ganglionic eminences. Cereb Cortex 2003; 13: 252–264.

  16. 16

    Flames N, Long JE, Garratt AN et al: Short- and long-range attraction of cortical GABAergic interneurons by neuregulin-1. Neuron 2004; 44: 251–261.

  17. 17

    Kitamura K, Yanazawa M, Sugiyama N et al: Mutation of ARX causes abnormal development of forebrain and testes in mice and X-linked lissencephaly with abnormal genitalia in humans. Nat Genet 2002; 32: 359–369.

  18. 18

    Poirier K, Van Esch H, Friocourt G et al: Neuroanatomical distribution of ARX in brain and its localisation in GABAergic neurons. Brain Res Mol Brain Res 2004; 122: 35–46.

  19. 19

    Kato M, Saitoh S, Kamei A et al: A longer polyalanine expansion mutation in the ARX gene causes early infantile epileptic encephalopathy with suppression-burst pattern (Ohtahara syndrome). Am J Hum Genet 2007; 81: 361–366.

  20. 20

    Archer HL, Evans J, Edwards S et al: CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients. J Med Genet 2006; 43: 729–734.

  21. 21

    Van Esch H, Jansen A, Bauters M, Froyen G, Fryns JP : Encephalopathy and bilateral cataract in a boy with an interstitial deletion of Xp22 comprising the CDKL5 and NHS genes. Am J Med Genet A 2007; 143: 364–369.

  22. 22

    Bahi-Buisson N, Kaminska A, Boddaert N et al: The three stages of epilepsy in patients with CDKL5 mutations. Epilepsia 2008; 49: 1027–1037.

  23. 23

    Weaving LS, Christodoulou J, Williamson SL et al: Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. Am J Hum Genet 2004; 75: 1079–1093.

  24. 24

    Tao J, Van Esch H, Hagedorn-Greiwe M et al: Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation. Am J Hum Genet 2004; 75: 1149–1154.

  25. 25

    Pescucci C, Meloni I, Bruttini M et al: Chromosome 2 deletion encompassing the MAP2 gene in a patient with autism and Rett-like features. Clin Genet 2003; 64: 497–501.

Download references

Acknowledgements

We thank the family of the patients for their cooperation. LB is supported by the Geconcerteerde Onderzoeksactie 2006/12. HVE is a postdoctoral researcher of the Fund for Scientific Research Flanders (FWO-Vlaanderen), Belgium.

Author information

Correspondence to Hilde Van Esch.

Additional information

Conflict of interest

The authors declare that there are no conflicts of interest.

URLs: Ensembl, http://www.ensembl.org/; ILAE, http://www.ilae-epilepsy.org; OMIM, http://www.ncbi.nlm.nih.gov/omim/.

Rights and permissions

Reprints and Permissions

About this article

Keywords

  • early myoclonic encephalopathy
  • epilepsy
  • ErbB4
  • translocation

Further reading